newsfilter
← Latest News
Business Wire·

Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales

- Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – Acceleron Pharma Inc. (NASDAQ:XLRN), a bio